OTCMRLFTY
Market cap64mUSD
Dec 23, Last price
4.47USD
1D
-6.90%
1Q
73.20%
IPO
-77.66%
Name
Relief Therapeutics Holding SA
Chart & Performance
Profile
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 6,033 -0.79% | 6,081 83.11% | 3,321 | |||||||
Cost of revenue | 22,677 | 41,555 | 36,946 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (16,644) | (35,474) | (33,625) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (13,503) | (3,526) | (820) | |||||||
Tax Rate | ||||||||||
NOPAT | (3,141) | (31,948) | (32,805) | |||||||
Net income | (98,181) 93.31% | (50,790) 46.35% | (34,705) 343.34% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 5,094 | 6,888 | 73,240 | |||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 861 | 2,096 | 1,676 | |||||||
Long-term debt | 4,705 | 2,248 | 2,588 | |||||||
Deferred revenue | 2,232 | 2,192 | ||||||||
Other long-term liabilities | 7,792 | 9,681 | 22,263 | |||||||
Net debt | (8,990) | (7,875) | (31,839) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (17,612) | (24,108) | (35,711) | |||||||
CAPEX | (446) | (521) | (13,708) | |||||||
Cash from investing activities | 8,695 | (8,017) | (30,269) | |||||||
Cash from financing activities | 4,050 | 6,417 | 67,689 | |||||||
FCF | (3,417) | (32,103) | (35,341) | |||||||
Balance | ||||||||||
Cash | 14,556 | 19,237 | 44,761 | |||||||
Long term investments | (7,018) | (8,658) | ||||||||
Excess cash | 14,254 | 11,915 | 35,937 | |||||||
Stockholders' equity | (155,951) | (58,163) | (22,992) | |||||||
Invested Capital | 218,927 | 217,258 | 230,563 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 11,752 | 10,570 | 8,983 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | (13,326) | (31,614) | (31,589) | |||||||
EV/EBITDA | ||||||||||
Interest | 330 | 196 | 268 | |||||||
Interest/NOPBT |